(-) trans 3-chloromethyl-4-(4-fluorophenyl)-1-methylpiperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (-) trans 3-chloromethyl-4-(4-fluorophenyl)-1-methylpiperidine
• 英文别名: 4-(4-fluorophenyl)-3-chloromethyl-N-methyl-piperidine；3-(chloromethyl)-4-(4-fluorophenyl)-1-methylpiperidine
• 化学式: C₁₃H₁₇ClFN
• 分子量: 241.736
• InChiKey: RYBSFHIQRSUBRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (-) trans 3-chloromethyl-4-(4-fluorophenyl)-1-methylpiperidine 在 四丁基氢氧化铵 作用下， 以 甲醇 、 异丙醇 、 甲苯 为溶剂， 以85%的产率得到N-甲基帕罗西汀
  参考文献：
  名称：

  Preparation of N-methylparoxetine and related intermediate compounds

  摘要：

  本发明提供了一种制备N-甲基帕罗西汀的方法，该方法中间体用于合成帕罗西汀，方法是通过将芝麻酚四丁基铵盐与CIPMA反应。先前的中间体合成产率特别低。使用芝麻酚四丁基铵盐可以将产率提高三倍以上。本发明不仅限于N-甲基帕罗西汀的合成，还包括其他类似化合物。

  公开号：

  US20020151567A1

文献信息

• Method of treating calcium overload in brain cells of mammals
  申请人：A/S Ferrosan

  公开号：US04877799A1

  公开（公告）日：1989-10-31

  Novel piperidine compounds having the formula ##STR1## wherein R.sup.3 is 3,4-methylenedioxyphenyl, aryl or heteroaryl which are optionally substituted with one or more C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, C.sub.3-8 -cycloalkyl, C.sub.3-5 -alkylene or aralkoxy, R.sup.1 is straight or branched C.sub.1-8 -alkyl, C.sub.4-8 -alkoxy-C.sub.4-8 -alkyl, C.sub.4-7 -cycloalkyl, aryloxy-C.sub.3-8 -alkyl, C.sub.4-8 -alkenyl, or C.sub.4-8 -cycloalkylalkyl, or R.sup.1 may also be hydrogen or C.sub.1-3 -alkyl, when R.sup.3 is aryl, which is substituted with two or more of C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, C.sub.3-8 -cycloalkyl, aralkoxy, or with C.sub.3-5 -alkylene. X is hydrogen or halogen, and wherein Y is O or S or a salt thereof with a pharmaceutically-acceptable acid, pharmaceutical compositions thereof, method-of-treating therewith. The novel compounds are useful in the treatment of anoxia, migraine, ischemia and epilepsy.

  新型哌啶化合物的化学式为##STR1##其中R.sup.3为3,4-亚甲二氧基苯基，芳基或杂芳基，可以选择地用一个或多个C.sub.1-6-烷基，C.sub.1-6-烷氧基，C.sub.3-8-环烷基，C.sub.3-5-烷基烯或芳基烷氧基取代，R.sup.1为直链或支链C.sub.1-8-烷基，C.sub.4-8-烷氧基-C.sub.4-8-烷基，C.sub.4-7-环烷基，芳氧基-C.sub.3-8-烷基，C.sub.4-8-烯基或C.sub.4-8-环烷基烷基，或者当R.sup.3为芳基时，R.sup.1也可以是氢或C.sub.1-3-烷基，该芳基被两个或更多的C.sub.1-6-烷基，C.sub.1-6-烷氧基，C.sub.3-8-环烷基，芳基烷氧基或C.sub.3-5-烷基烯取代。X为氢或卤素，Y为O或S或其与药用酸的盐，以及用于治疗的药物组合物，治疗方法。这些新型化合物在缺氧、偏头痛、缺血和癫痫的治疗中很有用。
• Process for the preparation of paroxetine substantially free of alkoxy impurities
  申请人：——

  公开号：US20030055256A1

  公开（公告）日：2003-03-20

  The present invention is directed to methods for preparing intermediates useful in the synthesis of paroxetine wherein the intermediates are substantially free of alkoxy impurities as well as to methods for preparing paroxetine and pharmaceutically acceptable salts thereof substantially free of alkoxy impurities. The alkoxy impurity is reacted with an ether cleaving agent to generate the corresponding phenol, which is separated, yielding the desired product substantially free of alkoxy impurities. Paroxetine intermediates such as PMA, paroxetine, and pharmaceutically acceptable salts thereof substantially free of alkoxy impurities also form part of the present invention.

  本发明涉及用于合成帕罗西汀的中间体的制备方法，其中的中间体基本上不含烷氧基杂质，还涉及基本上不含烷氧基杂质的帕罗西汀及其药学上可接受的盐的制备方法。烷氧基杂质与醚裂解剂反应生成相应的苯酚，分离苯酚后得到基本不含烷氧基杂质的所需产品。帕罗西汀中间体，如 PMA、帕罗西汀及其药学上可接受的盐，基本上不含烷氧基杂质，也是本发明的一部分。
• Piperidine compounds and their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0266574B1

  公开（公告）日：1994-01-05
• PROCESS FOR THE PREPARATION OF PAROXETINE AND SYNTHETIC INTERMEDITATES THEREOF
  申请人：SmithKline Beecham plc

  公开号：EP1246821A2

  公开（公告）日：2002-10-09
• EP1366041A4
  申请人：——

  公开号：EP1366041A4

  公开（公告）日：2004-12-22